{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:52:22Z","timestamp":1757623942559,"version":"3.44.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11095-025-03907-2","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T19:41:49Z","timestamp":1754941309000},"page":"1307-1314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Minipigs as a Non-clinical Model for Screening and Derisking Injection Site Reactions in Clinical Trials"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3773-429X","authenticated-orcid":false,"given":"Kaoutar","family":"Abbou Oucherif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiven","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronghua","family":"Bei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Berens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia L.","family":"Brown-Augsburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"3907_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jconrel.2020.02.036","volume":"321","author":"DS Collins","year":"2020","unstructured":"Collins DS, S\u00e1nchez-F\u00e9lix M, Badkar AV, Mrsny R. Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. J Control Release. 2020;321:475\u201382.","journal-title":"J Control Release"},{"issue":"2","key":"3907_CR2","doi-asserted-by":"publisher","first-page":"e12817","DOI":"10.1111\/dth.12817","volume":"32","author":"E Thomaidou","year":"2019","unstructured":"Thomaidou E, Ramot Y. Injection site reactions with the use of biological agents. Dermatol Ther. 2019;32(2):e12817.","journal-title":"Dermatol Ther"},{"issue":"10","key":"3907_CR3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/ni.2680","volume":"14","author":"WR Heath","year":"2013","unstructured":"Heath WR, Carbone FR. The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat Immunol. 2013;14(10):978\u201385.","journal-title":"Nat Immunol"},{"issue":"8","key":"3907_CR4","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.3390\/ijms20081811","volume":"20","author":"AV Nguyen","year":"2019","unstructured":"Nguyen AV, Soulika AM. The Dynamics of the Skin\u2019s Immune System. IJMS. 2019;20(8):1811.","journal-title":"IJMS"},{"issue":"4","key":"3907_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/12034754231188444","volume":"27","author":"PJ Kim","year":"2023","unstructured":"Kim PJ, Lansang RP, Vender R. A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections. J Cutan Med Surg. 2023;27(4):358\u201367.","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"3907_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bcp.12961","volume":"82","author":"L van Meer","year":"2016","unstructured":"van Meer L, Moerland M, Gallagher J, van Doorn MBA, Prens EP, Cohen AF, et al. Injection site reactions after subcutaneous oligonucleotide therapy. Brit J Clinical Pharma. 2016;82(2):340\u201351.","journal-title":"Brit J Clinical Pharma"},{"issue":"2","key":"3907_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00296-011-2096-3","volume":"32","author":"C Kaiser","year":"2012","unstructured":"Kaiser C, Knight A, Nordstr\u00f6m D, Pettersson T, Fransson J, Florin-Robertsson E, et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int. 2012;32(2):295\u20139.","journal-title":"Rheumatol Int"},{"issue":"4","key":"3907_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/01.qai.0000185313.48933.2c","volume":"40","author":"B Trottier","year":"2005","unstructured":"Trottier B, Walmsley S, Reynes J, Piliero P, O\u2019Hearn M, Nelson M, et al. Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks. JAIDS J Acquir Immune Defic Syndr. 2005;40(4):413\u201321.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"1","key":"3907_CR9","doi-asserted-by":"publisher","first-page":"2304027","DOI":"10.1080\/09546634.2024.2304027","volume":"35","author":"F Martora","year":"2024","unstructured":"Martora F, Patruno C, D\u2019Ascenzo S, Napolitano M. Injection site reactions after dupilumab or tralokinumab for atopic dermatitis. J Dermatol Treat. 2024;35(1):2304027.","journal-title":"J Dermatol Treat"},{"issue":"05","key":"3907_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1055\/s-0042-101241","volume":"124","author":"A MacDonald","year":"2016","unstructured":"MacDonald A, Ambery P, Donaldson J, Hicks K, Keymeulen B, Parkin J. Subcutaneous Administration of Otelixizumab is Limited by Injection Site Reactions: Results of an Exploratory Study in Type 1 Diabetes Mellitus Patients. Exp Clin Endocrinol Diabetes. 2016;124(05):288\u201393.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"3907_CR11","unstructured":"A Study of LY3322207 in Healthy Participants and in Participants With Hypertension (High Blood Pressure). ClinicalTrials.gov. 2019. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03590860 Accessed 21 June 2024."},{"issue":"1","key":"3907_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1006\/rtph.2000.1399","volume":"32","author":"H Olson","year":"2000","unstructured":"Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, et al. Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals. Regul Toxicol Pharmacol. 2000;32(1):56\u201367.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"3907_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/toxsci\/kfw050","volume":"151","author":"JA Willy","year":"2016","unstructured":"Willy JA, Schulte NE, Kreklau EL, Walgren JL, Renninger ML, Baker TK. In Vitro L6 Irritation Assay Predicts Clinical Injection Site Reactions for Small Molecules. Toxicol Sci. 2016;151(2):302\u201311.","journal-title":"Toxicol Sci"},{"issue":"1","key":"3907_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/1547691X.2021.1877375","volume":"18","author":"LM John","year":"2021","unstructured":"John LM, Dalsgaard CM, Jeppesen CB, Conde-Frieboes KW, Baumann K, Knudsen NPH, et al. In vitro prediction of in vivo pseudo-allergenic response via MRGPRX2. J Immunotoxicol. 2021;18(1):30\u20136.","journal-title":"J Immunotoxicol"},{"issue":"10","key":"3907_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/exd.14160","volume":"29","author":"C Jardet","year":"2020","unstructured":"Jardet C, David A, Braun E, Descargues P, Grolleau J, Hebsgaard J, et al. Development and characterization of a human Th17-driven ex vivo skin inflammation model. Exp Dermatol. 2020;29(10):993\u20131003.","journal-title":"Exp Dermatol"},{"issue":"1","key":"3907_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1089\/aivt.2014.0010","volume":"1","author":"B De Wever","year":"2015","unstructured":"De Wever B, Kurdykowski S, Descargues P. Human Skin Models for Research Applications in Pharmacology and Toxicology: Introducing NativeSkin \u00ae, the \u201cMissing Link\u201d Bridging Cell Culture and\/or Reconstructed Skin Models and Human Clinical Testing. Appl In Vitro Toxicol. 2015;1(1):26\u201332.","journal-title":"Appl In Vitro Toxicol"},{"issue":"3","key":"3907_CR17","first-page":"226","volume":"3","author":"WR Douglas","year":"1972","unstructured":"Douglas WR. Of pigs and men and research: A review of applications and analogies of the pig, sus scrofa, in human medical research. Space Life Sciences. 1972;3(3):226\u201334.","journal-title":"Space Life Sciences"},{"issue":"6","key":"3907_CR18","doi-asserted-by":"publisher","first-page":"H3109","DOI":"10.1152\/ajpheart.01223.2006","volume":"292","author":"R Sharma","year":"2007","unstructured":"Sharma R, Wang W, Rasmussen JC, Joshi A, Houston JP, Adams KE, et al. Quantitative imaging of lymph function. Am J Physiol-Heart Circ Physiol. 2007;292(6):H3109\u201318.","journal-title":"Am J Physiol-Heart Circ Physiol"},{"issue":"1","key":"3907_CR19","first-page":"94","volume":"59","author":"EH Rosh","year":"1977","unstructured":"Rosh EH, Vistnes LM, Ksander GA. The panniculus carnosus in the domestic pic: Plastic and Reconstructive Surgery. 1977;59(1):94\u20137.","journal-title":"The panniculus carnosus in the domestic pic: Plastic and Reconstructive Surgery"},{"issue":"1","key":"3907_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0169-409X(00)00076-4","volume":"43","author":"S Hammond","year":"2000","unstructured":"Hammond S. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv Drug Deliv Rev. 2000;43(1):45\u201355.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"3907_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","volume":"14","author":"WF Richter","year":"2012","unstructured":"Richter WF, Bhansali SG, Morris ME. Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration. AAPS J. 2012;14(3):559\u201370.","journal-title":"AAPS J"},{"issue":"1","key":"3907_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-2164-6-70","volume":"6","author":"R Wernersson","year":"2005","unstructured":"Wernersson R, Schierup MH, J\u00f8rgensen FG, Gorodkin J, Panitz F, St\u00e6rfeldt HH, et al. Pigs in sequence space: A 0.66X coverage pig genome survey based on shotgun sequencing. BMC Genomics. 2005;6(1):70.","journal-title":"BMC Genomics"},{"issue":"2","key":"3907_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.dci.2014.03.022","volume":"45","author":"KH Mair","year":"2014","unstructured":"Mair KH, Sedlak C, K\u00e4ser T, Pasternak A, Levast B, Gerner W, et al. The porcine innate immune system: An update. Dev Comp Immunol. 2014;45(2):321\u201343.","journal-title":"Dev Comp Immunol"},{"issue":"1","key":"3907_CR24","doi-asserted-by":"publisher","first-page":"9613","DOI":"10.1038\/s41598-017-10110-w","volume":"7","author":"H Kim","year":"2017","unstructured":"Kim H, Park H, Lee SJ. Effective method for drug injection into subcutaneous tissue. Sci Rep. 2017;7(1):9613.","journal-title":"Sci Rep"},{"issue":"2","key":"3907_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4161\/mabs.4.2.19387","volume":"4","author":"Y Zheng","year":"2012","unstructured":"Zheng Y, Tesar DB, Benincosa L, Birnb\u00f6ck H, Boswell CA, Bumbaca D, et al. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. mAbs. 2012;4(2):243\u201355.","journal-title":"mAbs"},{"issue":"1","key":"3907_CR26","first-page":"112","volume":"157","author":"A Braendli-Baiocco","year":"2017","unstructured":"Braendli-Baiocco A, Festag M, Dumong Erichsen K, Persson R, Mihatsch MJ, Fisker N, Funk J, Mohr S, Constien R, Ploix C, Brady K. From the cover: the minipig is a suitable non-rodent model in the safety assessment of single stranded oligonucleotides. Toxicol Sci. 2017;157(1):112\u201328.","journal-title":"Toxicol Sci."},{"issue":"1","key":"3907_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3109\/1547691X.2012.735274","volume":"10","author":"GJD van Mierlo","year":"2013","unstructured":"van Mierlo GJD, Cnubben NHP, Kuper CF, Wolthoorn J, van Meeteren-Kreikamp AP, Nagtegaal MM, et al. The G\u00f6ttingen minipig \u00ae as an alternative non-rodent species for immunogenicity testing: A demonstrator study using the IL-1 receptor antagonist anakinra. J Immunotoxicol. 2013;10(1):96\u2013105.","journal-title":"J Immunotoxicol"},{"issue":"1","key":"3907_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3109\/1547691X.2013.796023","volume":"11","author":"GJD van Mierlo","year":"2014","unstructured":"van Mierlo GJD, Cnubben NHP, Wouters D, Wolbink GJ, Hart MHL, Rispens T, et al. The minipig as an alternative non-rodent model for immunogenicity testing using the TNF\u03b1 blockers adalimumab and infliximab. J Immunotoxicol. 2014;11(1):62\u201371.","journal-title":"J Immunotoxicol"},{"issue":"9","key":"3907_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1939-4551-1-9-145","volume":"1","author":"FER Simon","year":"2008","unstructured":"Simon FER, Simons KJ. H1 Antihistamines: Current Status and Future Directions. World Allergy Organ J. 2008;1(9):145\u201355.","journal-title":"World Allergy Organ J"},{"issue":"3\u20134","key":"3907_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.vetimm.2008.05.028","volume":"125","author":"P Rupa","year":"2008","unstructured":"Rupa P, Hamilton K, Cirinna M, Wilkie BN. Porcine IgE in the context of experimental food allergy: Purification and isotype-specific antibodies. Vet Immunol Immunopathol. 2008;125(3\u20134):303\u201314.","journal-title":"Vet Immunol Immunopathol"},{"issue":"5","key":"3907_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/1523-1747.ep12507592","volume":"78","author":"MP James","year":"1982","unstructured":"James MP, Kennedy AR, Eady RAJ. A Microscopic Study of Inflammatory Reactions in Human Skin Induced by Histamine and Compound 48\/80. J Investig Dermatol. 1982;78(5):406\u201313.","journal-title":"J Investig Dermatol"},{"key":"3907_CR32","unstructured":"FIRAZYR (icatibant) Injection, for subcutaneous use. Shire Pharmaceuticals. https:\/\/pi.shirecontent.com\/PI\/PDFs\/Firazyr_USA_ENG.pdf.\u00a0 Accessed\u00a0 21 June 2024."},{"key":"3907_CR33","unstructured":"FIRAZYR (icatibant) Injection, for subcutaneous use. FDA. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022150s016lbl.pdf.\u00a0Accessed 21\u00a0 June 2024."},{"issue":"1","key":"3907_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12249-020-01880-0","volume":"22","author":"GH Shi","year":"2021","unstructured":"Shi GH, Connor RJ, Collins DS, Kang DW. Subcutaneous Injection Performance in Yucatan Miniature Pigs with and without Human Hyaluronidase and Auto-injector Tolerability in Humans. AAPS PharmSciTech. 2021;22(1):39.","journal-title":"AAPS PharmSciTech"},{"issue":"4\u20135","key":"3907_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.etp.2008.04.003","volume":"60","author":"JA Engelhardt","year":"2008","unstructured":"Engelhardt JA. Predictivity of animal studies for human injection site reactions with parenteral drug products. Exp Toxicol Pathol. 2008;60(4\u20135):323\u20137.","journal-title":"Exp Toxicol Pathol"},{"issue":"2","key":"3907_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1600-0625.2011.01410.x","volume":"21","author":"M Maurer","year":"2012","unstructured":"Maurer M, Church MK. Inflammatory skin responses induced by icatibant injection are mast cell mediated and attenuated by H 1 -antihistamines. Exp Dermatol. 2012;21(2):154\u20135.","journal-title":"Exp Dermatol"},{"issue":"11","key":"3907_CR37","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1038\/jid.2009.134","volume":"129","author":"K Weller","year":"2009","unstructured":"Weller K, Maurer M. Desloratadine Inhibits Human Skin Mast Cell Activation and Histamine Release. J Investig Dermatol. 2009;129(11):2723\u20136.","journal-title":"J Investig Dermatol"},{"issue":"5","key":"3907_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5582\/ddt.2022.01067","volume":"16","author":"R Fujimura","year":"2022","unstructured":"Fujimura R, Asada A, Aizawa M, Kazama I. Cetirizine more potently exerts mast cell-stabilizing property than diphenhydramine. DD&T. 2022;16(5):245\u201350.","journal-title":"DD&T"},{"issue":"2018","key":"3907_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9524075","volume":"27","author":"ACCC Branco","year":"2018","unstructured":"Branco ACCC, Yoshikawa FSY, Pietrobon AJ, Sato MN. Role of Histamine in Modulating the Immune Response and Inflammation. Mediators Inflamm. 2018;27(2018):1\u201310.","journal-title":"Mediators Inflamm"},{"key":"3907_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1006\/taap.1994.1144","volume":"127","author":"K M\u00fcller-Decker","year":"1994","unstructured":"M\u00fcller-Decker K, F\u00fcrstenberger G, Marks F. Keratinocyte-derived proinflammatory key mediators and cell viability as in vitro parameters of skin irritancy: a possible alternative to the Draize skin irritation test. Toxicol Appl Pharmacol. 1994;127:99\u2013108.","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03907-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03907-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03907-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:28:29Z","timestamp":1757413709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03907-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3907"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03907-2","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"type":"print","value":"0724-8741"},{"type":"electronic","value":"1573-904X"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors were employed by Eli Lilly at the time of submission of this manuscript and may hold stock and\/or stock interests in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}